Zhao Feng, Yu Xiaokai, Xu Mengyou, Ye Sunyi, Zang Shoumei, Zhong Weixiang, Ren Guoping, Chen Xin, Yan Senxiang
Department of Radiation Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Graduate School, College of Medicine, Zhejiang University, Hangzhou, China.
Front Oncol. 2020 Jan 9;9:1467. doi: 10.3389/fonc.2019.01467. eCollection 2019.
Mucinous prostate cancer (PCa) is an extremely rare form of prostate malignancy. To date, the limited knowledge of its biology and outcomes stems from mostly small, single institution experiences. We analyzed the Surveillance, Epidemiology, and End Results (SEER) database to explore the incidence and treatment of mucinous PCa together with its prognostic factors to gain relatively large and consolidated insights. Age-adjusted incidence (AAI) rates were evaluated over time. Propensity score matching (PSM) and Kaplan-Meier analyses were used to compare the prognosis between mucinous PCa and typical prostate acinar adenocarcinoma. We assessed cancer-specific survival (CSS) and overall survival (OS) after patient stratification according to summary stage and treatment choice. Cox hazards regression analysis was performed to determine independent predictors of CSS and OS. The AAI in 2016 was 0.24 per million. Patients with mucinous PCa had similar CSS and OS to matched individuals with typical prostate acinar adenocarcinoma. In terms of treatment, 65.3% of mucinous PCa patients underwent surgery, and 23.9% received radiation therapy. Patients who underwent surgery had longer survival (CSS, = 0.012; OS, < 0.001), and patients who received radiation therapy had similar survival to those who did not receive radiation therapy (CSS, = 0.794; OS, = 0.097). A multivariate Cox analysis for CSS and OS showed that older age (CSS: HR: 4.982, = 0.001; OS: HR: 4.258, < 0.001) and distant stage (CSS: HR: 40.224, < 0.001; OS: HR: 9.866, < 0.001) were independent prognostic factors for mucinous PCa patients. Mucinous PCa has an extremely low AAI. Analysis of its outcomes indicates that it is not a more malignant tumor as previously suspected. Mucinous PCa shows a similar prognosis to typical prostate acinar carcinoma. Surgery was associated with prolonged survival. An older age at diagnosis and distant stage was associated with poor survival.
黏液性前列腺癌(PCa)是一种极其罕见的前列腺恶性肿瘤形式。迄今为止,对其生物学特性和预后的了解有限,主要源于大多是小型的单机构经验。我们分析了监测、流行病学和最终结果(SEER)数据库,以探讨黏液性PCa的发病率、治疗及其预后因素,从而获得相对大规模且综合的见解。随时间评估年龄调整发病率(AAI)率。采用倾向评分匹配(PSM)和Kaplan-Meier分析来比较黏液性PCa与典型前列腺腺泡腺癌之间的预后。我们根据总结分期和治疗选择对患者进行分层后评估癌症特异性生存(CSS)和总生存(OS)。进行Cox风险回归分析以确定CSS和OS的独立预测因素。2016年的AAI为百万分之0.24。黏液性PCa患者的CSS和OS与匹配的典型前列腺腺泡腺癌患者相似。在治疗方面,65.3%的黏液性PCa患者接受了手术,23.9%接受了放射治疗。接受手术的患者生存时间更长(CSS, = 0.012;OS, < 0.001),接受放射治疗的患者与未接受放射治疗的患者生存情况相似(CSS, = 0.794;OS, = 0.097)。对CSS和OS的多变量Cox分析表明,年龄较大(CSS:HR:4.982, = 0.001;OS:HR:4.258, < 0.001)和远处分期(CSS:HR:40.224, < 0.001;OS:HR:9.866, < 0.001)是黏液性PCa患者的独立预后因素。黏液性PCa的AAI极低。对其预后的分析表明,它并非如先前怀疑的那样是一种恶性程度更高的肿瘤。黏液性PCa的预后与典型前列腺腺泡癌相似。手术与生存期延长相关。诊断时年龄较大和远处分期与生存不良相关。